This brand name is authorized in South Africa
The drug EMINASE contains one active pharmaceutical ingredient (API):
|
1
Anistreplase
UNII 5O8V541HJ6 - ANISTREPLASE
|
|
Anistreplase is a thrombolytic drug, also known as anisoylated plasminogen streptokinase activator complex (APSAC). Eminase is a lyophilized formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). It is used in the emergency treatment of myocardial infarction and pulmonary emboli. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| B01AD03 | Anistreplase | B Blood and blood forming organs → B01 Antithrombotic agents → B01A Antithrombotic agents → B01AD Enzymes |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: ZA | Health Products Regulatory Authority | Identifier(s): Y/31.1/169 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
